Drug Trial Radar · NCT04154488
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 16, 2021
Primary completion
Aug 27, 2024
Study completion Aug 27, 2024
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people living with chronic neutropenia (including congenital, idiopathic, and cyclic). In Part 2 (Phase 2), the safety and tolerability of chronic dosing of mavorixafor will be evaluated in a larger participant population and the impact of 6-month chronic dosing of mavorixafor on participant neutropenia.
Conditions
- Neutropenia
Interventions
MavorixaforDrug
Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of MavorixaforTime frame: Baseline through Day 1 and 7 days follow-up
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Multiple Doses of MavorixaforTime frame: Baseline through Month 6 and 30 days follow-up
- Change From Baseline in Absolute Neutrophil Count (ANC) to 8 hours Post-dose On Day 1Time frame: Baseline, 8 hours Post-dose On Day 1
- Change From Baseline in ANC to Month 6Time frame: Baseline, Month 6
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
USF Health Department of Pediatrics
St. Petersburg, Florida
University of Iowa Hospital and Clinics
Iowa City, Iowa
University of Michigan
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Texas, Southwestern
Dallas, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.